SciELO - Scientific Electronic Library Online

SciELO - Scientific Electronic Library Online

Article References

VALLANO FERRAZ, Antonio; AGUSTI ESCASANY, Antonia; PEDROS XOLVI, Consuelo  and  ARNAU DE BOLOS, Josep M.ª. Revisión sistemática de los estudios de evaluación del coste de las reacciones adversas a medicamentos. Gac Sanit [online]. 2012, vol.26, n.3, pp. 277-283. ISSN 0213-9111.  http://dx.doi.org/10.1016/j.gaceta.2011.09.014.

    1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998; 279:1200-5. [ Links ]

    2. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis and management. Lancet. 2000; 356:1255-9. [ Links ]

    3. WHO, Collaborating Center for International Drug Monitoring. Definitions -as adopted by national centers participating in the WHO international drug monitoring program. BMJ. 1992; 304:465. [ Links ]

    4. Estudio APEAS. Estudio sobre la seguridad de los pacientes en atencin primaria de salud. Madrid: Ministerio de Sanidad y Consumo; 2008. [ Links ]

    5. Otero MJ, Domnguez-Gil A. Acontecimientos adversos por medicamentos: una patologa emergente. Farm Hosp. 2000; 24:258-66. [ Links ]

    6. Rodrguez-Mongui R, Otero MJ, Rovira J. Assessing the economic impact of adverse drug effects. Pharmacoeconomics. 2003; 21:623-50. [ Links ]

    7. Muehlberger N, Schneeweisss S, Hasford J. Adverse drug reaction monitoring - cost and benefit considerations, Part I: frequency of adverse drug reactions causing hospital admissions. Pharmacoepidemiol Drug Saf. 1997; 6(Suppl 3):71-7. [ Links ]

    8. Goettler M, Schneeweisss S, Hasford J. Adverse drug reaction monitoring - cost and benefit considerations, Part II: cost and preventibility of adverse drug reactions leading to hospital admissions. Pharmacoepidemiol Drug Saf. 1997; 6(Suppl 3):79-90. [ Links ]

    9. Lundkvist J, Jnsson B. Pharmacoeconomics of adverse drug reactions. Fundamental & Clinical Pharmacology. 2004; 18:275-80. [ Links ]

    10. Gautier S, Bachelet H, Bordet R, et al. The cost of adverse drug reactions. Exp Opin Pharmacother. 2003; 4:319-26. [ Links ]

    11. Real Decreto 1344/2007, de 11 de octubre, por el que se regula la farmacovigilancia de medicamentos de uso humano. Disponible en: http://www.boe.es/aeboe/consultas/bases_datos/doc.php?id=BOE-A-2007-18919. [ Links ]

    12. Snchez LA. Farmacoeconoma aplicada: evaluacin y uso de datos farmacoeconmicos de la literatura. Rev Esp Econ Salud. 2002; 1:41-50. [ Links ]

    13. Schneider PJ, Gift MG, Lee YP, et al. Cost of medication-related problems at a university hospital. Am J Health Syst Pharm. 1995; 52:2415-8. [ Links ]

    14. Johnson JA, Bootman JL. Drug-related morbidity and mortality. A cost of illness model. Arch Intern Med. 1995; 1949-56. [ Links ]

    15. Dartnell JG, Anderson JG, Cholan V, et al. Hospitalisation for adverse events related to drug therapy: incidence, avoidability and costs. Med J Aust. 1996; 164:659-62. [ Links ]

    16. Dennehy CE, Kishi DT, Louie C. Drug-related illness in emergency department patients. Am J Health Syst Pharm. 1996; 53:1422-6. [ Links ]

    17. Cullen DJ, Sweitzer BJ, Bates DW, et al. Preventable adverse drug events in hospitalized patients: a comparative study of intensive care and general care units. Crit Care Med. 1997; 25:1289-97. [ Links ]

    18. Bootman JL, Harrison DL, Cox E. The health care costs of drug-related morbidity and mortality in nursing facilities. Arch Intern Med. 1997; 157:2089-96. [ Links ]

    19. Johnson JA, Bootman LJ. Drug-related morbidity and mortality and the economic impact of pharmaceutical care. Am J Health Syst Pharm. 1997; 54:554-8. [ Links ]

    20. Otero Lpez MJ, Bajo Bajo A, Maderuelo Fernndez JA, et al. Evitabilidad de los acontecimientos adversos inducidos por medicamentos detectados en un servicio de urgencias. Rev Clin Esp. 1999; 199:796-805. [ Links ]

    21. Tafreshi MJ, Melbi MJ, Kaback KR, et al. Medication-related visits to the emergency department: a prospective study. Ann Pharmacother. 1999; 33:1252-7. [ Links ]

    22. Thomas EJ, Studdert DM, Newhouse JP, et al. Cost of medical injuries in Utah and Colorado. Inquiry. 1999; 36:255-64. [ Links ]

    23. Senst BL, Achusim LE, Genes RP, et al. Practical approach to determining costs and frequency of adverse drug events in a health care network. Am J Health-Syst Pharm. 2001; 58:1126-32. [ Links ]

    24. Ernst FR, Grizzle AJ. Drug-related morbidity and mortality: updating the cost of illness model. J Am Pharm Assoc. 2001; 41:192-9. [ Links ]

    25. Stoukides CA, D'Agostino PR, Kaufman MB. Adverse drug reaction surveillance in an emergency room. Am J Hosp Pharm. 1993; 50:712-4. [ Links ]

    26. Moore N, Briffaut C, Noblet C, et al. Indirect drug-related costs. Lancet. 1995; 345:588-9. [ Links ]

    27. Classen DC, Pestotnik S, Evans RS, et al. Adverse drug events in hospitalized patients, Excess length of stay, extra costs, and attributable mortality. JAMA. 1997; 277:301-6. [ Links ]

    28. Bates DW, Spell N, Cullen DJ, et al. The costs of adverse drug events in hospitalised patients. JAMA. 1997; 277:307-11. [ Links ]

    29. Lapeyre-Mestre M, Gary J, Machelard-Rougmanac M, et al. Incidence and cost of adverse drug reactions in a French cancer institute. Eur J Clin Pharmacol. 1997; 53:19-22. [ Links ]

    30. Moore N, Lecointre D, Noblet C, et al. Frequency and cost of serious adverse drug reactions in a department of general medicine. Br J Clin Pharmacol. 1998; 45:301-8. [ Links ]

    31. Ayani I, Aguirre C, Madariaga A, et al. A cost-analysis of suspected adverse drug reactions in a hospital emergency ward. Pharmacoepidemiol Drug Saf. 1999; 8:529-34. [ Links ]

    32. Lagnaoui R, Moore N, Fach J, et al. Adverse drug reactions in a department of systemic diseases-oriented internal medicine: prevalence, incidence, direct costs and avoidability. Eur J Clin Pharmacol. 2000; 55:181-6. [ Links ]

    33. Shu D-C, Woodall BS, Shin S-K, et al. Clinical and economic impact of adverse drug reactions in hospitalised patients. Ann Pharmacother. 2000; 34:1373-9. [ Links ]

    34. Pouyanne P, Haramburu F, Imbs JL, et al. Admissions to hospital caused by adverse drug reactions: cross-sectional incidence study. BMJ. 2000; 320:1036. [ Links ]

    35. Detourney B, Fagnani F, Pouyanne P, et al. Cot des hospitalisations pour effect indsirable mdicamenteux. Thrapie. 2000; 55:137-9. [ Links ]

    36. Dormann H, Muth-Selbach U, Krebs S, et al. Incidence and costs of adverse drug reactions during hospitalisation, Computarised monitoring versus stimulated spontaneous reporting. Drug Saf. 2000; 22:161-8. [ Links ]

    37. Bordet R, Gautier S, Le Louet H, et al. Analysis of the direct cost of adverse drug reactions in hospitalised patients. Eur J Clin Pharmacol. 2001; 56:935-41. [ Links ]

    38. Ramesh M, Pandit J, Parthasarathi G. Adverse drug reactions in a South Indian hospital - their severity and cost involved. Pharmacoepidemiol Drug Saf. 2003; 12:687-92. [ Links ]

    39. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. BMJ. 2004; 329:15-9. [ Links ]

    40. Dormann H, Neubert A, Criegge-Rieck M, et al. Readmissions and adverse drug reactions in internal medicine: the economic impact. J Intern Med. 2004; 255:653-63. [ Links ]

    41. Patel KJ, Kedia MS, Bajpai D, et al. Evaluation of the prevalence and economic burden of adverse drug reactions presenting to the medical emergency department of a tertiary referral centre: a prospective study. BMC Clinical Pharmacology. 2007; 7:8. [ Links ]

    42. Drummond M.F., Sculpher M.J., Torrance G.W., et al, editors. Methods for economic evaluation of health care programmes. 3rd edition. Oxford: Oxford University Press; 2005. p.400. [ Links ]

    43. Eisenberg JM. Clinical economics. A guide to economic analysis of clinical practices. JAMA. 1989; 262:2879-86. [ Links ]

    44. Puche Caas E, de Dios Luna J. Reacciones adversas a medicamentos: una revisin actualizada del problema en Espaa. Rev Clin Esp. 2006; 206:336-9. [ Links ]

    45. Pea C, Pujol M, Pallars R, et al. Estimacin del coste atribuible a la infeccin nosocomial: prolongacin de la estancia hospitalaria y clculo de los costes alternativos. Med Clin (Barc). 1996; 106:441-4. [ Links ]